Literature DB >> 16314052

EVI1 and hematopoietic disorders: history and perspectives.

Giuseppina Nucifora1, Leopoldo Laricchia-Robbio, Vitalyi Senyuk.   

Abstract

The ecotropic viral integration site 1 (EVI1) gene was identified almost 20 years ago as the integration site of an ecotropic retrovirus leading to murine myeloid leukemia. Since its identification, EVI1 has slowly been recognized as one of the most aggressive oncogenes associated with human leukemia. Despite the effort of many investigators, still very little is known about this gene. The mechanism by which EVI1 operates in the transformation of hematopoietic cells is not known, but it is clear that EVI1 upregulates cell proliferation, impairs cell differentiation, and induces cell transformation. In this review, we summarize the biochemical properties of EVI1 and the effects of EVI1 in biological models.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16314052     DOI： 10.1016/j.gene.2005.09.020

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  35 in total

1.  Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; Nerea Marcotegui; Ana Conchillo; Elisabet Guruceaga; José Roman-Gomez; María J Calasanz; Xabier Agirre; Felipe Prosper; María D Odero
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-07       Impact factor: 11.205

2.  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Authors:  Emilie A Bard-Chapeau; Justin Jeyakani; Chung H Kok; Julius Muller; Belinda Q Chua; Jayantha Gunaratne; Arsen Batagov; Piroon Jenjaroenpun; Vladimir A Kuznetsov; Chia-Lin Wei; Richard J D'Andrea; Guillaume Bourque; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

3.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.

Authors:  Olga S Kustikova; Hartmut Geiger; Zhixiong Li; Martijn H Brugman; Stuart M Chambers; Chad A Shaw; Karin Pike-Overzet; Dick de Ridder; Frank J T Staal; Gottfried von Keudell; Kerstin Cornils; Kalpana Jekumar Nattamai; Ute Modlich; Gerard Wagemaker; Margaret A Goodell; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

4.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

5.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

6.  Reducing the genotoxic potential of retroviral vectors.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2008

7.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.

Authors:  Ute Modlich; Susana Navarro; Daniela Zychlinski; Tobias Maetzig; Sabine Knoess; Martijn H Brugman; Axel Schambach; Sabine Charrier; Anne Galy; Adrian J Thrasher; Juan Bueren; Christopher Baum
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

8.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

9.  Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Authors:  Lovisa Osterberg; Kristina Levan; Karolina Partheen; Ulla Delle; Björn Olsson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

10.  Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.

Authors:  Veronique Voisin; Philippe Legault; Diana Paulina Salazar Ospina; Yaacov Ben-David; Eric Rassart
Journal:  BMC Med Genomics       Date:  2010-01-26       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.